Skip to NavigationSkip to content


Research finds blood-thinners protect against dementia

Blood-thinning drugs are commonly used to reduce stroke risk in patients with atrial fibrillation (AF) but research from the Karolinska Institute suggests that anticoagulants may also protect patients from dementia.

Studies had previously pointed towards an association and researchers decided to examine 444,106 patients’ with AF’s records to determine if they could find a clear link. When compiled together, the research found that those taking anticoagulants to prevent blood clots had a 29% lowered risk of developing dementia compared to those who were not.

FDA approves Boehringer’s Pradaxa reversal agent

BI building at night

The FDA has approved Boehringer Ingelheim’s Praxbind, a reversal agent for its anticoagulant Pradaxa.

The US regulator approved Praxbind (idarucizumab) for use when reversal of the anticoagulant effect of dabigatran is needed for emergency surgery or uncontrolled bleeding.

Pradaxa (dabigatran etexilate) was the first in a new class of anticoagulants to be approved, and is now marketed in over 100 countries as offering comparable blood-thinning effects to warfarin without the need for ongoing monitoring.

NICE recommends Daiichi’s Lixiana for blood clots

Daiichi Sankyo
Daiichi has earned NICE approval for its newly-launched drug Lixiana

Daiichi Sankyo has won a speedy approval from NICE, after the NHS guidance body approved its newly-launched blood clotting drug Lixiana as a treatment for clots in the legs and lungs.

The NICE decision comes just days after Daiichi launched Lixiana (edoxaban) in the UK, and shortly after the Japanese firm earned European approval for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults and the prevention of stroke and clots in adults with

Daiichi Sankyo launches clotting drug Lixiana in UK

Daiichi image
Daiichi Sankyo's Lixiana is the fourth new anticoagulant to hit the UK market

Daiichi Sankyo’s Lixiana has become the latest pharma offering in the class of newer oral anticoagulants in the UK.

Lixiana (edoxaban) reduces the risk of blood clots in people with atrial fibrillation, which is thought to be the commonest heart rhythm disorder.

NICE recommends Xarelto for stroke prevention

Xarelto picture

NICE is recommending Bayer’s anticoagulant pill Xarelto to help reduce the risk of stroke in certain patients. 

The watchdog’s final guidance recommends Xarelto (rivaroxaban), a Factor Xa inhibitor, as an option for the prevention of stroke and systemic embolism in people with atrial fibrillation. 

Its licence is specifically for patients with non-valvular atrial fibrillation who have one or more risk factors such as congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, prior stroke or transient ischaemic attack. 

Xarelto receives FDA approval

Bayer J&J Xarelto (rivaroxaban)

Bayer and Johnson & Johnson’s oral blood thinner Xarelto has been approved in the US for the prevention of deep vein thrombosis after surgery.

Xarelto (rivaroxaban), a Factor Xa inhibitor, is now approved for the prevention of deep vein thrombosis that could lead to a pulmonary embolism in patients undergoing knee or hip replacement surgery in the US, where J&J holds the marketing rights to the drug.

Digital Pharma: Roche launches online warfarin training for patients

Roche has launched an online training tool to help UK patients on long-term warfarin learn about anticoagulation self-monitoring.

The CoaguChek Academy aims to improve patients’ quality of life and reduce the amount of training needed from health care professionals.

Allison Rossiter, Director of Point of Care at Roche, said: “Making this educational tool available to patients throughout the UK will help promote the importance of self-testing whilst at the same time deliver tangible benefits to patients and clinicians.”

Merck drops oral anticoagulant

Merck & Co

Merck has given the rights to its oral anticoagulant betrixaban back to Portola Pharmaceuticals after a review of its late stage portfolio.

Betrixaban, an oral Factor Xa inhibitor, is being studied in a phase II trial for the prevention of stroke in patients with atrial fibrillation. The company's decision looks to be based on doubts about the drug's ability to compete in an increasingly competitive therapeutic area.

Merck suffers late-stage blow to vorapaxar

An increased risk of bleeding caused by pipeline drug vorapaxar has dealt Merck a major blow.

The Data and Safety Monitoring Board overseeing the study of the drug in acute coronary syndrome (ACS) patients says one phase III study should be halted and another study should only continue in a sub-group of patients.

The anticoagulant is aimed at preventing a second heart attacks or stroke in people who had already suffered one, but the results suggest it raises the risk of strokes because of excess bleeding.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches